Hereditary Cancer Panel denied as not FDA-approved for this use by Carelon (formerly AIM)?

NCCN-aligned for hereditary cancer testing. Pre-test genetic counseling required for many panels. Avalon overlap in some plans.

GC by ABGC-certified counselor (telegenetics qualifies). NCCN BOP/COL footnotes endorse multi-gene panels when >1 syndrome on differential. Reroute to in-network lab if denial is contractual.

## Why Carelon Denied Your Hereditary Cancer Panel as Not FDA-Approved

Carelon (formerly AIM Specialty Health) sometimes issues "not FDA-approved" denials for laboratory-developed tests (LDTs), including hereditary cancer panels. This denial type reflects a specific regulatory status argument: many genetic panels are developed and validated internally by laboratories under CLIA certification rather than through the FDA's premarket approval or 510(k) pathway. Carelon may use this as grounds to deny coverage, but this framing is legally and clinically contestable.

## Why This Denial Is Appealable

The vast majority of hereditary cancer panels offered by major clinical laboratories are laboratory-developed tests regulated under the Clinical Laboratory Improvement Amendments (CLIA) through CMS, not through FDA approval. This regulatory pathway is well-established and widely accepted by professional medical societies, including those that publish hereditary cancer guidelines. Coverage policies that categorically deny LDTs as "not FDA-approved" are generally inconsistent with prevailing medical standards — and external reviewers frequently find that CLIA-certified LDTs meet the "generally accepted standards of medical practice" required under ACA external review standards.

If the specific panel ordered does carry FDA clearance or approval, that should be documented and submitted as well.

## Federal Appeal Framework

• Internal Appeal: ACA and ERISA §503 guarantee a full-and-fair internal appeal. File within the deadline on your denial notice.
• External Review: Under ACA §2719, after a final internal denial, you are entitled to independent external review by an accredited IRO, generally within four months. The IRO applies a "generally accepted standards of medical practice" standard — not a strict FDA-approval test. Expedited review is available for urgent situations.
• ERISA Plans: Request the complete claims file and the specific policy language defining "approved" tests.

## Concrete Appeal Steps and Timeline

1. Request the specific policy language — determine whether Carelon's policy requires FDA approval or whether CLIA certification is a permitted pathway. 2. Obtain the laboratory's CLIA certification and accreditation documentation (e.g., CAP accreditation). 3. Have your prescriber document the clinical necessity and the laboratory's validated performance characteristics. 4. File internal appeal, citing CLIA regulatory pathway and professional society guideline support. 5. File external review if internal appeal is denied — this is a favorable denial type for external review.

## Documentation to Gather

• Laboratory's CLIA certificate and any additional accreditation (CAP, NY State approval, etc.)
• Laboratory's analytical and clinical validation documentation
• FDA clearance or approval documentation if applicable to the specific panel
• Prescriber medical-necessity letter addressing the clinical indication
• Current applicable guideline from the relevant professional organization (such as NCCN) endorsing the test for the indication — obtain directly from that organization
• The specific Carelon coverage policy and evidence criteria applied — request these in the appeal process

## Criteria-Mapping Structure

For each component of the denial, document your response:

| Denial Component | Your Supporting Evidence | |---|---| | Test not FDA-approved | CLIA certificate; explanation of LDT regulatory pathway; FDA clearance docs if available | | Test not validated | Lab's analytical/clinical validation summary; CAP accreditation | | Clinical indication not established | Prescriber letter; guideline support from applicable professional organization |

External reviewers applying the ACA standard of "generally accepted medical practice" routinely find that CLIA-certified, guideline-endorsed hereditary cancer panels meet coverage criteria regardless of FDA approval status.